FREVIVA

About

The most frequent clinical course of multiple sclerosis (MS) manifests as relapsing remitting MS (RRMS), characterized by initial episodes of transient neurological compromise (synonymously called relapses, clinical exacerbations or attacks) with variable recovery (remissions), eventually leading to cumulative deficits that may increase acutely with each new relapse. After several years of disease, the clinical features of the disease change and symptoms and signs of MS start to gradually worsen with (relapsing secondary progressive MS) or without superimposed relapses (non-relapsing secondary progressive MS).

The goal of this study is to assess the efficacy of frexalimab compared to
placebo in delaying disability progression, and its safety and tolerability in adult participants with nonrelapsing secondary progressive MS.